Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

This was the stock's third consecutive day of losses.

Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $4.24 per share in its upcoming release, pointing to a year-over-year increase of 133.1%. It is ...

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and ...

The stock's fall snapped a three-day winning streak.